Policies, codes and standards
GSK Code of Conduct
- Code of Conduct (English)PDF - 2.8MB
- Arabic PDF - 1.6MB
- Chinese - Simplified PDF - 1.9MB
- Czech PDF - 1.6MB
- FrenchPDF - 1.6MB
- GermanPDF - 1.6MB
- HindiPDF - 1.7MB
- HungarianPDF - 1.6MB
- Indonesian PDF - 1.6MB
- ItalianPDF - 1.5MB
- JapanesePDF - 2.3MB
- KoreanPDF - 1.8MB
- MalayPDF - 1.5MB
- PolishPDF - 1.6MB
- Portuguese - Brazil PDF - 1.6MB
- Portuguese - EUPDF - 1.6MB
- RomanianPDF - 1.6MB
- RussianPDF - 1.6MB
- Spanish - EUPDF - 1.5MB
- ThaiPDF - 1.6MB
- Traditional ChinesePDF - 1.9MB
- TurkishPDF - 1.5MB
- UrduPDF - 1.7MB
- VietnamesePDF - 1.8MB
Anti-Bribery and Corruption (ABAC) Programme
The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption. The programme includes an ABAC Policy and Standard, which have been designed to help staff and external parties understand bribery and corruption risk, and their responsibilities to actively combat it.
- Anti-Bribery and Corruption PolicyPDF - 347.0KB
Binding Corporate Rules
Our human resources and research and development activities involve the processing of “personal information”, including the transfer of that personal information internationally. We have adopted Binding Corporate Rules (BCRs) to enable us to make international transfers of personal information within our group of companies in compliance with data protection laws of the European Union, in particular the General Data Protection Regulation (Regulation 2016/679) (GDPR).
Find out more about GSK’s Binding Corporate Rules
Third Party Oversight Programme
Our Third Party Oversight Programme helps control risks from third party business engagements with suppliers, distributors and other business partners. We want to work with business partners who share our commitment of high ethical standards and operating in a responsible way.
- Working with Third Parties PDF - 252.4KB
GSK’s public policy statement on Working with Third Parties sets out our expectation that Third Parties will:
- Share our commitment to high ethical standards
- Comply with all applicable laws and regulations and adopt, at a minimum, GSK’s Anti-Bribery & Corruption and Labour Rights Principles
- Where relevant, comply with our standards on quality, patient safety, health and safety and the environment
- Create a culture which supports staff reporting of suspected violations of law, rules and regulations, as well as of unethical conduct, without fear of reprisal or retaliation.
Promotion and Scientific Engagement
- GSK Pharma and Vaccine Code of Practice for Promotion and Scientific EngagementPDF - 214.0KB
- GSK Consumer Healthcare Code of Promotion and Scientific EngagementPDF - 908.2KB
Find out more about us
GSK access and developing countries
- Patents and access to medicines in developing countriesPDF - 188.1KB
- Technology transfer, capacity building and developing countriesPDF - 99.3KB
- Tiered pricing and vaccinesPDF - 150.2KB
- Civil society organisations and vaccine procurementPDF - 152.3KB
GSK and research & development
- Our Approach to Clinical TrialsPDF - 85.3KB
- Combating antimicrobial resistancePDF - 208.8KB
- Cloning and Stem Cell TechnologiesPDF - 66.9KB
- The convention on biological diversityPDF - 68.3KB
- Public disclosure of clinical researchPDF - 225.3KB
- The care, welfare and treatment of animalsPDF - 68.8KB
GSK and intellectual property
- Incremental innovationPDF - 52.6KB
- Compulsory licensingPDF - 195.1KB
- EvergreeningPDF - 57.5KB
- A disclosure requirement in patent lawPDF - 74.9KB
- Regulatory data protectionPDF - 72.8KB
GSK and the environment
- Hazardous chemicals managementPDF - 64.3KB
- Genetically modified micro-organisms and Environment, Health and Safety (EHS)PDF - 206.0KB
- NanotechnologyPDF - 65.3KB
- Respiratory Products and Global WarmingPDF - 26.2KB
- Pharmaceuticals in environmentPDF - 206.5KB
- The impact of climate change on healthPDF - 54.6KB
- Climate Change and GSK’s OperationsPDF - 196.3KB
- Water stewardshipPDF - 144.2KB
- Deforestation-free sourcingPDF - 156.0KB
GSK and public health
- Tackling Global Health ChallengesPDF - 182.8KB
- Falsified and Substandard Healthcare productsPDF - 165.6KB
- PharmacovigilancePDF - 161.3KB
- Engagement with patient organisationsPDF - 317.6KB
- Compassionate usePDF - 194.9KB
GSK and business integrity
- Conflict mineralsPDF - 195.5KB
- Competitiveness and investment criteriaPDF - 55.6KB
- Human rightsPDF - 144.6KB
- Marketing practices and scientific engagementPDF - 60.5KB
- Product donationsPDF - 85.1KB
- Safeguarding personal informationPDF - 196.3KB
- Tax strategyPDF - 260.9KB
- Political AdvocacyPDF - 295.8KB
- Working with third partiesPDF - 252.4KB
- Lethal InjectionsPDF - 79.0KB
Find out more about us
- Modern Slavery Act statement 2019PDF - 214.5KB
- Modern Slavery Act statement 2018PDF - 144.6KB
- Modern Slavery Act statement 2017PDF - 208.8KB
- Modern Slavery Act statement 2016PDF - 214.0KB
GlaxoSmithKline plc - Specialised Disclosure Report
- GlaxoSmithKline plc - 2019 Form SD Conflict Minerals DisclosurePDF - 16.4KB
- GlaxoSmithKline plc - 2018 Form SD Conflict Minerals DisclosurePDF - 289.5KB
- GlaxoSmithKline plc - 2017 Form SD Conflict Minerals DisclosurePDF - 240.5KB
- GlaxoSmithKline plc - 2016 Form SD Conflict Minerals DisclosurePDF - 1.2MB
- GlaxoSmithKline plc - 2015 Form SD Conflict Minerals DisclosureDOC - 46.5KB
- GlaxoSmithKline plc - 2014 Form SD Conflict Minerals DisclosurePDF - 122.5KB
GlaxoSmithKline plc and GlaxoSmithKline Capital plc Euro Medium Term Note Programme
- GlaxoSmithKline Euro Medium Term Note Programme – Supplementary Prospectus Nov 2020PDF - 60.6KB
- Glaxosmithkline Euro Medium Term Note Programme Prospectus Document 2020PDF - 1.5MB
- GlaxoSmithKline Euro Medium Term Note Programme – Supplementary Prospectus 2020PDF - 73.2KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2019PDF - 1.3MB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2018PDF - 1.1MB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2017PDF - 506.4KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2016PDF - 464.3KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2015PDF - 470.4KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014PDF - 462.2KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2013PDF - 3.4MB
- GlaxoSmithKline Euro Medium Term Note Programme – Registration DocumentPDF - 86.6KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus DocumentPDF - 3.4MB
- GlaxoSmithKline Euro Medium Term Note Programme - Supplementary Prospectus DocumentPDF - 127.0KB
GlaxoSmithKline Capital plc Annual Reports
- 2020 Half Year Results And Interim Management Report GlaxoSmithKline Capital PlcPDF - 229.4KB
- 2019 Annual Report GlaxoSmithKline Capital plcPDF - 596.3KB
- 2019 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 188.0KB
- 2018 Annual Report GlaxoSmithKline Capital plcPDF - 420.1KB
- 2018 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 426.7KB
- 2017 Annual Report GlaxoSmithKline Capital plcPDF - 741.4KB
- 2017 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 300.9KB
- 2016 Annual Report GlaxoSmithKline Capital plcPDF - 7.3MB
- 2016 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 360.4KB
- 2015 Annual Report GlaxoSmithKline Capital plcPDF - 690.5KB
- 2015 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 342.2KB
- 2014 Annual Report GlaxoSmithKline Capital plcPDF - 7.9MB
- 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 68.2KB
- 2013 Annual Report GlaxoSmithKline Capital plcPDF - 330.7KB
- 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 2.1MB
- 2012 Annual Report GlaxoSmithKline Capital plcPDF - 539.8KB
- 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 182.0KB
- 2011 Annual Report GlaxoSmithKline Capital plcPDF - 617.4KB
- 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 301.3KB
- 2010 Annual Report GlaxoSmithKline Capital plcPDF - 4.9MB
- 2009 Annual Report GlaxoSmithKline Capital plcPDF - 2.9MB
- 2008 Annual Report GlaxoSmithKline Capital plcPDF - 3.5MB
UK Pension Schemes Statements of Investment Principles (SIP)
The links below will allow you to download the Statements of Investment Principles for the main UK pension schemes.
The contents of these documents are set out under UK law and cover the investment policies of the schemes in the following broad areas: Risk Measurement and Management, Implementation and Governance. The documents also provide details of the asset allocation of the investments.
The Statements have been agreed by the Trustee Boards on the basis of written advice from their appointed external investment advisers and lawyers. There is a consultation process on the SIP with the participating employers as required by law.
The Statements are reviewed by the Trustees annually and also if there are any significant changes to the investment policies.
The Trustees monitor compliance with this statement at least annually. Fund manager activity is reviewed quarterly through reports prepared by investment consultants. Additionally, meetings are held with fund managers at least annually to review the activities and compliance with their contractual terms and with the Statements of Investment Principles.
- GSK Pension Fund SIPPDF - 333.8KB
- GSK Pension Scheme SIPPDF - 338.0KB
- GW Contracted-out Money Purchase Scheme SIPPDF - 276.0KB
- SB Senior Executive Pension Plan SIPPDF - 322.6KB
- SB Pension Plan SIPPDF - 346.0KB
Socially Responsible Investing
Socially Responsible Investing (SRI) is most commonly understood to mean investing in a manner that takes into account the impact of investments on wider society and the natural environment, both today and in the future. The Trustee of the GSK Pension Plans annually reviews its SRI policies as part of the Trustee business planning process, and the GSK Pension Plans publish ‘Statements of Investment Principles’ which provide a high level overview of the SRI policies.
The Trustee aims to be an engaged and responsible long-term investor in the assets and markets in which it invests. The Trustee believes that the integration of environmental, social and governance (ESG) factors within investment managers’ investment processes is not detrimental to the risk and the sustainable long-term expected returns from pension schemes’ investments.
The Trustee does not wish to interfere with the day to day investment decisions of its investment managers. However, the Trustee does encourage its investment managers to comply with the principles outlined in the UN Principles for Responsible Investment and the UK Stewardship Code where this is appropriate for their mandate, as well as to take into account ESG considerations in the selection, retention and realisation of investments in so far as this is consistent with their overall objectives.
The Trustee regularly reviews the voting strategy of its investment managers. The Trustee also supports the principle of shareholder activism and, for relevant mandates, prefers its investment managers to have an explicit strategy, outlining the circumstances in which they will engage with a company on ESG matters and how they will measure the effectiveness of this strategy.
For GSK Pension Plans, the majority of the assets are managed by Legal and General Investment Management (LGIM). In particular, a portion of the Plans’ equity portfolio follows a low carbon investment philosophy by re-weighting away from carbon intensive assets. Companies with significant carbon emissions as well as those with large fossil fuel reserves are underweighted which, in turn, reduces the Plans’ carbon footprint as well as stranded asset risk. Overall, the mandate’s carbon footprint is around three-quarters lower than that of the parent index (MSCI World). Additionally, LGIM complies with the principles set out in the UK Stewardship Code and LGIM are also a signatory to the UN Principles for Responsible Investment. In addition, LGIM maintain a large, dedicated team which is responsible for ESG monitoring and which is actively engaged in encouraging companies to improve their ESG standards.
A detailed review of LGIM’s ESG activities, including examples of LGIM’s engagement activities with companies, can be found in the Corporate Governance Report below.
- Corporate Governance ReportPDF - 8.5MB